LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

5-Minute Multiplex PCR Testing System to Redefine Point-Of-Care Diagnostics

By LabMedica International staff writers
Posted on 06 Aug 2024
Print article
Image: The LEX 5-minute diagnostics platform provides an answer faster and with less hands-on effort than any existing product on the market (Photo courtesy of LEX Diagnostics)
Image: The LEX 5-minute diagnostics platform provides an answer faster and with less hands-on effort than any existing product on the market (Photo courtesy of LEX Diagnostics)

Point of care (POC) testing provides significant clinical benefits, particularly when results can be obtained quickly enough to inform clinical decisions during a single consultation, eliminating the need for follow-up visits. Such rapid diagnostics can significantly reduce costs by minimizing both the number of patient-clinician interactions required for diagnosis and treatment decisions and the need for patients to make multiple trips to the healthcare facility for a single episode of illness. Typically, POC molecular diagnostic tests can produce results within about an hour. Now, a low-cost instrument aims to redefine POC diagnostics by delivering molecular tests at the time they are most needed.

LEX Diagnostics (Melbourn, UK) is developing a PCR molecular system that offers both high speed and high sensitivity, capable of completing a test in less than 10 minutes and reporting positive results in as little as 5 minutes. This ensures that results are available quickly enough to impact clinical decisions within the same appointment. The LEX system is designed around a cartridge that receives a dry swab and conducts all necessary sample preparation, processing, and analysis internally, without the need for manual sample elution or other preparatory steps. This design not only speeds up the process but also confines all sample handling within the system, reducing the manual effort required and minimizing the exposure risk for healthcare workers.

The device's ability to provide rapid yet sensitive PCR testing is facilitated by innovative thermal cycling technology and proprietary LEX reagents. Unlike traditional systems that rely on Peltier devices, which can be costly and less reliable, LEX’s patented thermal cycler technology allows for extremely quick heating and cooling, maintaining precise thermal control. This capability ensures that enzyme-driven amplification processes are optimized for speed without sacrificing sensitivity, making rapid PCR diagnostics feasible at the POC. The LEX system is suitable for settings with a CLIA waiver, including urgent care centers, pharmacies, and physician offices.

The LEX system is capable of delivering positive results in just 5 minutes and can perform multiplex testing to identify and differentiate between Flu A, Flu B, and COVID-19. Negative results are delivered in under 10 minutes. LEX is also planning to expand its range of respiratory tests to include rapid assays for RSV and Strep A, which are expected to be completed in about 5 minutes. With the development of its second-generation instrument, LEX aims to add testing for sexually transmitted infections (STIs) to its portfolio.

Related Links:
LEX Diagnostics

Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.